What This Means
This study looked at licochalcone A, a compound from licorice, as a possible way to protect against metabolic-associated fatty liver disease (MAFLD), a common chronic liver condition. In mice with MAFLD, the compound reduced fat buildup in the liver, oxidative stress, and inflammation.
The researchers traced how this happens. Licochalcone A appeared to switch on AMPK, a key cellular energy and fat-metabolism regulator, by changing a chemical modification on proteins called O-GlcNAcylation. It also improved the gut barrier and shifted gut bacteria, increasing groups such as Muribaculaceae and Parasutterella. Experiments that wiped out gut bacteria or transferred them between animals indicated that the gut microbes were needed for the liver benefits. A metabolite linked to this process, dodecanedioic acid, also helped through AMPK in mice and in cell experiments.
This research suggests that part of licochalcone A's liver benefit works through a gut-liver connection. The findings come from mice and cell models, so they do not show that the compound would work in people, and the abstract gives no dosing details.